|
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology
This book presents a comprehensive discussion on the heterogeneity
existing between different types of stem cells within the same
tissue, for several types of cancers, e.g. glioblastoma stem cells.
Recent developments have revealed completely different roles of
distinct stem cells within the same organ. Thus, Stem Cells
Heterogeneity in Cancer provides a timely update us on the current
information on stem cells heterogeneity in various tissues. It also
provides a solid foundation of the history of stem cells from
specific tissues and the current applications of this knowledge in
regenerative medicine. When taken as a whole, alongside its
companion volumes Stem Cells Heterogeneity - Novel Concepts, and
Stem Cells Heterogeneity in Different Organs, these three books
present a comprehensive reference on stem cell heterogeneity in
various tissues and current and future applications for
regenerative medicine. It is essential reading for advanced cell
biology students as well as researchers in stem cells and
clinicians.
This book approaches the differential diagnosis and management of
rare, hereditary cancer syndromes from a practical angle,
addressing the issues pertinent to each tumour type as encountered
by health professionals in their day-to-day practice. This book
enables readers to correctly identify patients with rare cancer
syndromes who would benefit from genetic counselling and testing,
and provides the necessary knowledge for appropriate patient
management and advising at-risk family members. It begins by
describing recent advances in genetic testing for
cancer-predisposing genes. Leading experts from Europe and
Australia then offer detailed, up-to-date guidance on the diagnosis
and management of a wide range of hereditary cancers. The
concluding chapter examines the wider issues that are raised by
genetic testing for rare cancer syndromes for patients, families
and health professionals. This book is an invaluable source of
information for all specialists involved in the care of such
patients and their families.
The volume will serve as a primer on tyrosine kinase signaling and
its importance in cancer. The volume will first introduce the
common denominators of small-molecule and antibody-derived
inhibitors, as well as the general phenomenon of resistance. The
volume will then detail resistance to the most commonly used
classes of tyrosine kinase inhibitors, and will focus specific
chapters on resistance to BCR-ABL1, FLT3, angiokinase family
members, and ALK inhibitors.
Michael Sand gives the reader an overview of current techniques in
expression profiling of miRNAs and their maturation machinery in
the skin. This book is a postdoctoral thesis on miRNAs in cutaneous
malignant melanoma and non-melanoma skin cancer with a focus on the
miRNA processing machinery and miRNA expression profiling. The
research presented in this book was performed in the Dermatologic
Surgery Section at the Department of Dermatology, Venereology and
Allergology of the Ruhr-University Bochum, Germany and gives the
reader an overview of current techniques in expression profiling of
miRNAs and their maturation machinery in the skin.
Nuclear Oncogenes as Transcription Factors.- Control of Hepatocyte
Growth by Positive and Negative Growth Regulators and Mitogenic
Triggers: Implications for Hepatic Neoplasia.- Cell Cycle Dependent
Regulation of Poly(ADP-Ribose) Polymerase Gene Expression.-
Different Expression of Cell Cycle Related Genes During Liver
Regeneration and Liver Hyperplasia.- S-Adenosylmethionine Content,
DNA Methylation and Gene Expression in Regenerating Liver.- Gene
Activation and Deactivation During Multistage Hepatocarcinogenesis
in the Rat.- Biochemical and Molecular Perturbations Induced in
Preneoplastic Tissue by a S-Adenosyl-L-Methionine Load.-
Alterations of Cell Surface Receptors and Expression of Cellular
Oncogenes in the Liver of Rats Fed a Hypolipidemic Peroxisome
Proliferator.- Growth Hormone-Regulated Expression of c-myc Gene
During sex-Differentiated Promotion of Rat Liver Carcinogenesis.-
In Situ Hybridization of Ha-Ras During Rat Liver Carcinogenesis.-
Mutations in the H-Ras Proto-Oncogene in Early Precancerous Liver
Lesions of the B6C3F1 Mouse.- Transformation of Human Epithelial
Cells by Recombinant Human Papillomavirus DNA Associated with
Cervical Cancer.- Cancer Families and Susceptibility to Cancer.-
Cancer Syndromes in Humans.- Case-Control Studies on Cancer Risk in
G6PD-Deficient Male Populations.- Genetic Susceptibility to Murine
Hepatocarcinogenesis.- MHC-Linked Genes Controlling Growth and
Reproduction Influence the Susceptibility to
Diethylnitrosamine-Induced Carcinogenesis.- Metabolic Aberrations
and Metamorphosis During Chemical Carcinogenesis.- Persistent Rat
Liver Nodules Differ from Normal Liver, Regenerating Liver and
Early Nodules both in Terms of Proteins of the Nuclear Matrix and
Chromatin Condensation.- Intracellular Na+, K+, H+ and Cl?
Activities and Membrane Potentials During the
4-Dimethylaminoazobenzene-Induced Rat Hepatocarcinogenesis.-
Analysis of the Effects of Modifying Agents on Proliferation and
Enzyme Phenotype in Focal Preneoplastic and Neoplastic Liver
Lesions in Rats.- Epidermal Growth Factor-Induced Cell
Proliferation and EGF Binding in Preneoplastic Foci in The Rat
Liver.- The Different Calcium Requirements of the Mitogenic Effects
Elicited in Primary Neonatal Rat Hapatocytes by the Diterpene
Phorbol Esters 12-O-Tetradecanoylphorbol-13-Acetate and Sapintoxin
A.- Glucose-6-Phosphate Dehydrogenase Molecular Forms in Different
Experimental Models of Hepatic Cell Proliferation.- Estrogen
Dependent Growth of a Rat Pituitary Tumor (MtT/F84).- Deterministic
Coupling Between Cellular Bioenergetics, Cholesterol Synthesis,
cell Proliferation and Cancer.- Dolichyl Phosphate as a Regulator
of Cell Growth.- Regulation of Cholesterol Metabolism in Normal and
Malignantly Transformed Tissue in Vivo.- Cholesterol Metabolism and
Proliferative Processes.- Serum LCAT and Lipid Levels in grc--
Bearing Rats with Liver Cancer.- Covalent Modification of Proteins
by Farnesol and the Control of Cell Proliferation.- Repeated
Treatments with a Low HNE Concentration Affect K562 Cell
Proliferation.- Arachidonic Acid Enrichment Augments the
Malonildialdehyde Production in Yoshida AH-130 Hepatoma Cells.-
Modulation of Phosphatidylinositol-4,5-Diphosphate
(PIP2)-Phospholipase C Activity by 4-Hydroxyalkenals.- The Role of
Hepatic Metabolism in Sex Differentiation of Chemical
Hepatocarcinogenesis in the Rat.- Changes of Rat Liver Glutathione
Peroxidase, Glutathione Reductase and Glutathione Transferase 7-7
by Lead Nitrate Treatment.- High Affinity P-450 Form for the
Metabolic Activation of DEN in Liver of Acetone-Induced Rats but
not of Hamsters.- Genotoxicity of Chloroethanes and Structure
Activity Relationships.- Genetical and Biochemical Studies on Three
Halogenated Ethanes.- "In Vivo" Interaction of Methionine and
Cysteine Sulfur with Rat Liver tRNA.- Synthesis and Secretion of
Cathepsin D in Normal And Tumor Human Cells.- Relationship Between
Cell Proliferation and Cell Death.- An in Vitro Model for
Apoptosis: Uptake a...
This book focuses on the analysis of cancer dynamics and the
mathematically based synthesis of anticancer therapy. It summarizes
the current state-of-the-art in this field and clarifies common
misconceptions about mathematical modeling in cancer. Additionally,
it encourages closer cooperation between engineers, physicians and
mathematicians by showing the clear benefits of this without
stating unrealistic goals. Development of therapy protocols is
realized from an engineering point of view, such as the search for
a solution to a specific control-optimization problem. Since in the
case of cancer patients, consecutive measurements providing
information about the current state of the disease are not
available, the control laws are derived for an open loop structure.
Different forms of therapy are incorporated into the models, from
chemotherapy and antiangiogenic therapy to immunotherapy and gene
therapy, but the class of models introduced is broad enough to
incorporate other forms of therapy as well. The book begins with an
analysis of cell cycle control, moving on to control effects on
cell population and structured models and finally the signaling
pathways involved in carcinogenesis and their influence on therapy
outcome. It also discusses the incorporation of intracellular
processes using signaling pathway models, since the successful
treatment of cancer based on analysis of intracellular processes,
might soon be a reality. It brings together various aspects of
modeling anticancer therapies, which until now have been
distributed over a wide range of literature. Written for
researchers and graduate students interested in the use of
mathematical and engineering tools in biomedicine with special
emphasis on applications in cancer diagnosis and treatment, this
self-contained book can be easily understood with only a minimal
basic knowledge of control and system engineering methods as well
as the biology of cancer. Its interdisciplinary character and the
authors' extensive experience in cooperating with clinicians and
biologists make it interesting reading for researchers from control
and system engineering looking for applications of their knowledge.
Systems and molecular biologists as well as clinicians will also
find new inspiration for their research.
Advances in Cancer Research, Volume 152, the latest release in this
ongoing, well-regarded serial, provides invaluable information on
the exciting and fast-moving field of cancer research.
Each chapter will focus on the known molecular characteristics of
specific childhood cancers, focusing on how the molecular 'drivers'
can be exploited from a therapeutic standpoint with currently
available targeted agents. Where applicable, integration of
targeted therapies with conventional cytotoxic agents will be
considered. This volume will provide a comprehensive summary of
molecular characteristics of childhood cancers, and how the changes
involved in transformation provide us with opportunities for
developing relatively less toxic, but curative, therapies.
This volume provides detailed descriptions of prevailing and novel
techniques used by experts in the study of PTEN function in disease
and biology. The book begins with chapters exploring methods to
detect expression levels of PTEN in normal and diseased human
specimens; methods to evaluate specific PTEN function in brain
cancer; methods that utilize a new biosensor to measure PTEN
regulation; and techniques to measure post-transcriptional
regulation of PTEN by micoRNAs and ceRNAs. Other chapters present
methods describing novel techniques to detect PTEN localization and
previously unstudied structural features of PTEN measured through
X-Ray Crystallography and Hydrogen Deuterium Exchange Mass
Spectrometry. The book concludes with methods to study PTEN
function in model organisms including mice and C. elegans. Written
in the highly successful Methods in Molecular Biology series
format, chapters include introductions to their respective topics,
lists of the necessary materials and reagents, step-by-step,
readily reproducible laboratory protocols, and tips on
troubleshooting and avoiding known pitfalls. Authoritative and
thorough, PTEN: Methods and Protocols is a valuable collection of
methodologies and protocols useful to researchers who are
interested in the PTEN field.
A behind-the-scenes look inside three key trials involving
Monsanto's weed killer Roundup, cancer, and the search for
justice—written by an expert witness medical oncologist who lived
it all. For years, Monsanto declared that their product Roundup,
the world's most widely used weed killer, was safe. But that all
changed in 2015, when the International Agency for Research on
Cancer (IARC) analyzed data from scientific studies and concluded
that glyphosate, the active ingredient in Roundup, is probably
carcinogenic. The Environmental Protection Agency (EPA)
disagreed, other regulatory agencies got involved, and scientists
clamored to understand the link between glyphosate and cancer.
Toxic Exposure tells the true story of numerous patients who
developed non-Hodgkin lymphoma, a form of cancer, after using
Roundup and their ensuing trials against Monsanto (now owned by
Bayer, one of the largest agrochemical companies in the world).
Written by Chadi Nabhan, MD, MBA, a cancer specialist, this is the
only book written by an expert physician witness who testified in
the first three trials against Monsanto. Dr. Nabhan takes the
reader behind the scenes of these pivotal trials, explaining key
features of the cases, including how Monsanto downplayed the IARC's
scientific conclusions, may have worked to change how the EPA
classified glyphosate, and conducted extensive PR campaigns
designed to minimize the public's perception of the negative health
effects of its product. He also provides details about the other
expert witnesses who reviewed the evidence, analyzed the science,
and stood up to this agricultural behemoth in the courtroom. Dr.
Nabhan tells the inside story of corporate influence, courtroom
drama, legal discourse, monumental verdicts, and the ensuing media
frenzy surrounding this massive uncovering of the truth and the
years of scientific and legal work that led up to it.
Fluoropyrimidine Metabolism and Mechanism of Action.-
5-Fluoro-2?-Deoxyuridine: Role of Schedule in its Therapeutic
Efficacy.- Comparison of Continuous Infusions and Bolus Injections
of 5- Fluorouracil with or without Leucovorin: Implications for
Inhibition of Thymidylate Synthase.- Critical Questions for the
Future Direction of FU/LV.- Cellular Interactions Between the
Natural and Unnatural Isomers of 5-Formyltetrahydrofolate.-
Leucovorin as a Prodrug.- Clinical Use of Leucovorin: Intracellular
Metabolism.- Some Considerations Concerning the Dose and Schedule
of 5FU and Leucovorin: Toxicities of Two Dose Schedules from the
Intergroup Colon Adjuvant Trial (INT-0089).- Effects of
5-Fluorouracil on mRNA.- Genetic Variation in Thymidylate Synthase
Confers Resistance to 5-Fluorodeoxyuridine.- Experience with 5FU +
L-Leucovorin.- 5-Fluorouracil Combined with the Pure
[6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of
Patients with Advanced Colorectal Carcinoma: A Phase I-II Study of
Two Consecutive Regimens.- 5-Fluorouracil Modulation in Colorectal
Carcinoma: Experience of German Investigators.- An Overview of
Adjuvant Treatment of Colon Cancer.- Dose-Dependent Inhibition of
Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear
Cells in Patients Receiving N-Phosphonacetyl)-L-Aspartate.-
Alternative Approaches to Modulation of Fluoropyrimidines.-
Increasing the Efficacy of 5-Fluorouracil with Interferons:
Preclinical, Clinical, and Pharmacokinetic Studies.- Enchanced
Cytotoxicity of 5-Fluorouracil Combined with [6RS]-Leucovorin and
Recombinant Human Interferon-?2a in Colon Carcinoma Cells.-
Regulation of Thymidylate Synthase in Human Colon Cancer Cells
Treated with 5-Fluorouracil and Interferon-Gamma.- Biochemical
Modulation of 5-Fluorouracil by PALA: Mechanism of Action.-
Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy.-
Update on Metabolic Modulation as a Therapeutic Approach for Adult
Carcinomas.- Fluorouracil and Leucovorin in Advanced Breast
Cancer.- Fluorouracil Modulation in Head and Neck Cancer.-
Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches
in Europe.- Rationale for the Combination Therapy of 5FU and CDDP.-
Biochemical Modulation of Fluoropyrimidines: The "Giscad" Studies.-
New Drugs.- Clinical Experience with UFT in Japan.- Clinical
Studies of the Modulation of Ftorafur.- The Role of the
Reduced-Folate Carrier and Metabolism to Intracellular
Polyglutamates for the Activity of ICI D1694.- The History of the
Development and Clinical Use of CB 3717 and ICI D1694.- New Sites
of Intervention in the Development of New Drugs in Solid Tumors.-
P53: A Determinant of the Cell Cycle Response to DNA Damage.-
Therapeutic Implications of Molecular Genetics.- Concluding
Remarks.- Summary.- Abbreviations.- Author Index.
This book presents the theoretical foundations of Systems Biology,
as well as its application in studies on human hosts, pathogens and
associated diseases. This book presents several chapters written by
renowned experts in the field. Some topics discussed in depth in
this book include: computational modeling of multiresistant
bacteria, systems biology of cancer, systems immunology, networks
in systems biology.
Retinoids have received considerable attention in recent years and
due cognizance has been given to their versatility as biological
response modifiers, as evidenced by the virtually explosive growth
of literature in this field in the past few years. This volume has
been designed to give a current state-of-the-art picture of
retinoids. The perceived potential of retinoids in the treatment of
certain disease stated has initiated attempts at identifying and
synthesizing new retinoid derivatives with definable and selective
effects on aberrant biological phenomena. Appropriately, therefore,
we begin with the chemistry of retinoids and their derivatives
together with discussions of their biological activity. Major
advances have been made in understanding the mechanisms by which
retinoids modulate physiological and phenotypic traits of cells.
The transduction of retinoid signaling by the mediation of nuclear
receptors of the steroid/thyroid receptor superfamily has now been
studied extensively and the cloning and defining the
characteristics of these receptors has been a focus of discussion
in this volume. Retinoids also markedly modulate the transduction
of extracellular signals such as those imparted by growth factors
and hormones, and thus actively influence and control cellular
proliferative patterns. Retinoids can alter epidermal growth factor
receptor expression (Kawaguchi et al., 1994), responsiveness to
thyroid hormone (Esfandiari et al., 1994; Pallet et al., 1994),
inhibit the proliferative responses of hematopoietic progenitor
cells to granulocyte colony stimulating factor (Smeland et al.,
1994), and modulate secretion on interleukins by leukaemic cells
(Balitrand et al., 1994), among other things. This has obvious
implications for pharmacological manipulation of deregulated growth
(Dickens and Colletta, 1993; Mulshine et al., 1993). Apoptosis is
another component in the regulation of growth control. Apoptotic
cell death is influenced by several agents and retinoids may
function by interfering with apoptotic pathways of regulation of
growth control and quite legitimately, therefore, the importance of
this aspect of retinoid function has been duly recognized here.
The study of the molecular events leading to cellular
transformation and cancer has progressed significantly in the last
decade, and it has become apparent that many genes subject to
modification in cancer are, in fact, transcription factors that
govern the execution of the genetic programme of the cell.
Transcription factors can behave either as oncogenes or as tumour
suppressor genes. To date only a limited number of transcription
factors have been associated with cancer. This volume deals with
several transcription factor families that were first identified in
oncogenic retroviruses. Each chapter contains a description of the
structure of the transcription factors, the nature of target genes,
the regulation of their activities, and an explaination of how they
can deregulate cell growth and differentiation. This text should be
suitable for the specialist scientist and the advanced student
This volume presents state-of-the-art information on each of the
arms of the unfolded protein response (UPR), how their
activation/repression are regulated, integrated, and coordinated,
how UPR components affect cancer cell biology and responsiveness to
therapeutic interventions, and how UPR components/activities offer
potentially novel targets for drug discovery, repurposing, and
development. The volume will provide the most recent information on
the signaling and regulation of the UPR, explore examples of how
the UPR and/or specific components contribute to cancer biology,
and identify and explore specific examples of potently new
actionable targets for drug discovery and development from within
the UPR and its regulation. Unique to the volume will be a specific
focus on the UPR and its role in cancer biology, as well as a
discussion of the role of the UPR in drug responses and resistance
in cancer.
This book discusses the efficacy of various naturally occurring
chemopreventive agents in preventing or delaying cancer. It focuses
on the holistic chemopreventive concept, demonstrating the relevant
response is the combined effect of a series of compounds that alone
have been shown to have some effect in different experimental
models. Written by leading experts in the field, the contributions
provide details of research on various chemopreventive agents.
Offering insights into the unique molecular targets and mechanisms,
safety issues, molecular efficacy, and occurrence in nature of
these compounds, the book is a valuable resource for all scientists
working in biomedicine, and specifically in cancer research.
The tumor microenvironment has become a very important and hot
topic in cancer research within the past few years. The tumor
microenvironment is defined as the normal cells, molecules, and
blood vessels that surround and feed a tumor cell. As many
scientists have realized, studying the tumor microenvironment has
become critical to moving the field forward, since there are many
players in a tumor's localized and surrounding area, which can
significantly change cancer cell behavior. There is a dual
relationship wherein the tumor can change its microenvironment and
the microenvironment can affect how a tumor grows and spreads.
Tumor Microenvironment in Cancer Progression and Cancer Therapy
aims to shed light on the mechanisms, factors, and mediators that
are involved in the cancer cell environment. Recent studies have
demonstrated that in addition to promoting tumor progression and
protecting tumor cells from the spontaneous immune-mediated
rejection and different forms of cancer therapeutics, tumor
microenvironment can also be a target and mediator of both standard
and newly-emerging forms of cancer therapeutics. Thus, the dual
role of the tumor microenvironment is the integral focus of the
volume. The volume highlights the bi-directional interactions
between tumor cells and non-malignant tumor component during tumor
progression and treatment. It also focuses on the three groups of
the reactive tumor component: stromal cells, blood vessels and the
infiltrating immune cells. These three groups are discussed under
the lens of their role in promoting tumor growth, shielding the
tumor from rejection and from standard forms of cancer therapies.
They are emerging as targets and mediators of standard and new
forms of potential therapy.
This book describes in detail current best practice in the
diagnosis and treatment of malignant pediatric bone tumors and also
discusses other important aspects of management. Clinical
assessment, the role of different imaging modalities and choice of
biopsy procedure are explained and an individual chapter is devoted
to diagnostic pathology. The treatment-oriented chapters offer
in-depth descriptions of chemotherapeutic regimens, radiation
therapy, limb-salvage options and amputation-related issues and in
addition consider the approach to lung nodules, the role of
biomarkers, off-therapy monitoring and the treatment of relapse.
Psychosocial impacts and needs are addressed and guidance provided
on nursing during treatment and rehabilitation following
orthopaedic surgery. Closing chapters evaluate emerging therapies
and discuss disparate aspects of survivorship. The authors are
acknowledged experts and include many contributors from the
Nationwide Children's Hospital, a leading pediatric care facility
in the United States.
This book gives insight into the functional role of non-coding RNAs
in central pathways contributing to the development of obesity,
type 2 diabetes, non-alcoholic fatty liver disease,
atherosclerosis, myocardial infarction, cardiomyopathy, and heart
failure. It also sheds light on the relationship of this cluster
with cancer. Tumor cells, in contrast to cells in cardiometabolic
tissues, can regulate this cluster of non-coding RNAs to escape
from oxidative stress and anti-tumor immunity and maintain insulin
sensitivity, facilitating cancer progression. The book presents a
cluster of non-coding RNAs that may be prospectively analyzed in
extensive cohort studies to determine their value in
risk-predicting machine learning algorithms. In addition, it
emphasizes the role of microvesicles in communication between
tumor-adjacent tissue, inflammatory cells, and tumor cells, with a
special focus on the role of miR-155. The book intends to promote
interdisciplinary research. Due to the comprehensive background
information provided in each chapter, it is suitable for
researchers in academia and industry and for graduate students in
biology, bioengineering, and medicine.
|
You may like...
Wax on Crafts
Miriam Joy
Paperback
R619
R529
Discovery Miles 5 290
|